Filter by Year:
Press Releases
-
Apr 16, 2024
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
-
Apr 09, 2024
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
-
Apr 05, 2024
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
-
Mar 26, 2024
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
-
Mar 07, 2024
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
-
Mar 05, 2024
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909
-
Feb 28, 2024
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
-
Feb 08, 2024
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
-
Jan 08, 2024
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
-
Jan 03, 2024
Foghorn Therapeutics Announces CFO Departure
Displaying 1 - 10 of 80